AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
Avidity Biosciences Completes $690 Million Share Offering
ByAinvest
Monday, Sep 15, 2025 4:22 pm ET1min read
Avidity Biosciences has completed a $690 million share offering. The biopharmaceutical company is developing RNA therapeutics called antibody oligonucleotide conjugates (AOCs) to address previously unreachable targets and diseases. Its pipeline includes three clinical development programs: AOC 1001 for myotonic dystrophy type 1, AOC 1044 for Duchenne muscular dystrophy, and AOC 1020 for facioscapulohumeral muscular dystrophy.
Avidity Biosciences, Inc. has successfully completed a $690 million share offering. The biopharmaceutical company specializes in developing a new class of ribonucleic acid (RNA) therapeutics known as antibody oligonucleotide conjugates (AOCs). These AOCs combine the specificity of monoclonal antibodies with the precision of oligonucleotide therapies, enabling the treatment of previously unreachable targets and diseases.The company's expanding pipeline includes three clinical development programs. AOC 1001 is designed to treat people with myotonic dystrophy type 1 (DM1) and is currently in phase I/II development with the ongoing MARINA open label extension study (MARINA-OLE) [1]. AOC 1044 is designed for people with Duchenne muscular dystrophy and is in phase I/II development with the EXPLORE44 trial [1]. AOC 1020 is designed to treat people living with facioscapulohumeral muscular dystrophy (FSHD) and is in Phase I/II development with the FORTITUDE trial [1].
This latest funding round will support Avidity Biosciences' ongoing research and development efforts, particularly in advancing its pipeline of AOCs. The company aims to revolutionize the treatment landscape for rare and challenging diseases by leveraging the unique capabilities of its RNA therapeutics.
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet